Arkolith/Insider Trading/CCCC/Form 4

Mossler Mark

Chief Accounting OfficerC4 Therapeutics, Inc. (CCCC) · full profile →Form 4 · filed Feb 18, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 14, 2026Option exercise(M)9K—$075K
Feb 14, 2026Tax withholding(F)3K$1.89$6K72K
Feb 13, 2026Grant(A)57K—$075K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000174) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML